Your browser doesn't support javascript.
loading
METTL14-mediated m6A methylation of pri-miR-5099 to facilitate cardiomyocyte pyroptosis in myocardial infarction.
Yu, Hang; Li, Qing-Sui; Guo, Jun-Nan; Zhang, Zhen; Lang, Xian-Zhi; Liu, Yi-Ning; Qin, Long; Su, Xu; Zhang, Qing-Wei; Xue, Ya-Dong; Gong, Li-Ling; Xu, Ning; Li, Ming; Zhao, Wen-Shuang; Zhao, Xing-Miao; Zhang, Wan-Yu; Yao, Yi-Jing; Chen, Xi-Ming; Zhang, Zhen; Li, Wei; Wang, Han-Xiang; Cai, Ben-Zhi; Li, Jia-Min; Wang, Ning.
Afiliación
  • Yu H; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Li QS; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Guo JN; Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, 150040, China.
  • Zhang Z; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Lang XZ; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Liu YN; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Qin L; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Su X; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Zhang QW; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Xue YD; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Gong LL; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Xu N; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Li M; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Zhao WS; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Zhao XM; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Zhang WY; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Yao YJ; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Chen XM; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Zhang Z; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Li W; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Wang HX; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
  • Cai BZ; Department of Pharmacy at The Second Affiliated Hospital, and Department of Pharmacology (State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD)), College of Pharmacy, Harbin Medical University, Harbin, 150081, China. caibz@ems.hrbmu.edu.cn.
  • Li JM; Research Unit of Noninfectious Chronic Diseases in Frigid Zone (2019RU070), Chinese Academy of Medical Sciences, Harbin, 150081, China. caibz@ems.hrbmu.edu.cn.
  • Wang N; Northern Translational Medicine Research and Cooperation Center, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, 150080, China. caibz@ems.hrbmu.edu.cn.
Acta Pharmacol Sin ; 46(6): 1639-1651, 2025 Jun.
Article en En | MEDLINE | ID: mdl-39939804
N6-methyladenosine (m6A) modification is an important mechanism in microRNA processing and maturation. Previous studies show the involvement of pri-miRNA methylation in regulating the occurrence and development of tumor-related diseases. In this study, we investigated the role of its aberrant regulation in cardiac diseases. Myocardial infarction (MI) mouse were established by ligation of the left anterior descending branch of the coronary artery. We showed that the expression of methyltransferase 14 (METTL14) was significantly increased in myocardium of MI mice. We demonstrated that METTL14 methylated the primary transcript miRNA (pri-miR-5099), promoting the recognition by DiGeorge critical region 8 (DGCR8) and the maturation processing of pri-miR-5099. Mature microRNA-5099-3p (miR-5099-3p) inhibited the expression of E74 like ETS transcription factor 1 (ELF1), which transcriptionally regulated pyroptosis factors such as acysteinyl aspartate-specific proteinase 1 (caspase-1) and gasdermin D (GSDMD), ultimately leading to cardiomyocyte pyroptosis. This study reveals that myocardial infarction-induced miR-5099-3p excessive maturation via m6A modification promotes the development and progression of cardiomyocyte pyroptosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Adenosina / Miocitos Cardíacos / MicroARNs / Piroptosis / Metiltransferasas / Infarto del Miocardio Límite: Animals Idioma: En Revista: Acta pharmacol sin Asunto de la revista: FARMACOLOGIA Año: 2025 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Asunto principal: Adenosina / Miocitos Cardíacos / MicroARNs / Piroptosis / Metiltransferasas / Infarto del Miocardio Límite: Animals Idioma: En Revista: Acta pharmacol sin Asunto de la revista: FARMACOLOGIA Año: 2025 Tipo del documento: Article País de afiliación: China